Valued at a market cap of $10.8 billion, Charles River Laboratories International, Inc. (CRL) is a global contract research organization (CRO) headquartered in Wilmington, Massachusetts. It supports the drug discovery and development process for pharmaceutical, biotechnology, medical device, and government clients worldwide. It is expected to announce its fiscal Q4 earnings for 2025 soon. Before this event, analysts expect this healthcare company to report a profit of $2.33 per share, down 12.4% from $2. ...